About Aris Baras

Aris Baras, MD, MBA is a Senior Vice President at Regeneron, where he serves as the Founder and General Manager of the Regeneron Genetics Center (RGC), a wholly owned subsidiary, and as Co-Head of Regeneron Genetic Medicines (RGM). A physician-scientist, entrepreneur, and general manager, Dr. Baras has nearly two decades of experience building and leading teams spanning drug discovery and development, genetics and genetic medicines, business development & venture investing, and general management with P&L responsibility.

Dr. Baras has been part of Regeneron’s senior management team since 2018 and has held roles of increasing responsibility across research, clinical development, strategy, business development, and general management during his 15-year tenure at the company. He has been a part of Regeneron’s evolution from a small biotechnology company and its first approved product to a global biopharmaceutical leader with nearly 20,000 employees, a market capitalization that exceeded $100 billion, and more than a dozen approved and marketed medicines. He has played a significant role across much of Regeneron’s portfolio, including products such as Evkeeza®, Praluent®, and Dupixent®, as well as more than 50 programs spanning discovery and development across a broad range of therapeutic areas.

As Founder and General Manager of the RGC, Dr. Baras built and scaled the world’s largest genetics and proteomics engine for drug discovery and development. The RGC has delivered more than 40 novel drug targets and therapeutic programs into Regeneron’s pipeline, sequenced more than three million individuals on its way to ten million, and established over 150 global academic, health system, and biopharma partnerships totaling over $1B in investment. Under his leadership, the RGC pioneered large-scale discovery of protective genetic factors, enabling target discovery and therapeutics with significantly higher probabilities of success, and has become a leader in digital and predictive health. Dr. Baras has also led nearly $500 million of strategic investments by the RGC in genomics, health data and AI companies, and consumer health platforms, including DNAnexus, Truveta, and Ultima, alongside Google Ventures, Blackstone, and other leading investors.

Dr. Baras also serves as Co-Head of RGM, overseeing the company’s siRNA, gene editing, and gene therapy efforts. Starting from scratch, RGM has grown into a major engine of innovation, with a dozen programs in the clinic and accounting for more than one-third of Regeneron's new programs entering the pipeline. He has played a key role in advancing programs across gene therapy, RNA interference, and genome editing, including DB-OTO for congenital hearing loss, cemdisiran for complement-mediated diseases, multiple siRNA programs across fatty liver disease, obesity, cardiometabolic, and neurodegenerative disorders, and gene editing programs for transthyretin amyloidosis and alpha-1 antitrypsin deficiency. He helped establish and lead several of Regeneron’s largest strategic partnerships, including a broad, 20+ program collaboration with Alnylam Pharmaceuticals, as well as partnerships with Intellia, Tessera, and Mammoth, and the acquisition of Decibel Therapeutics.

Prior to Regeneron, Dr. Baras worked with the venture capital firm, Wakefield Group and their portfolio company, Liquidia, now a mid-cap biotech, where he played a critical role on the team that conceived of Yutrepia™. He conducted academic and translational research in immunology, oncology, and antibody-based therapeutics at Duke University and the National Institutes of Health in the labs of Tom Tedder, Kim Lyerly, and Steven Rosenberg. Dr. Baras currently serves on the boards of DNAnexus, Truveta, and the Duke Science and Technology Campaign. Dr. Baras has co-authored more than 100 publications in leading scientific and medical journals, including The New England Journal of Medicine, Science, Nature, Nature Genetics, Nature Medicine, JAMA, and The Lancet, and is an inventor on more than 25 issued or pending patents. He has been recognized by Pharmaceutical Executive as a top leader in biopharma, by PharmaVoice as a gene therapy pioneer, by Business Insider as one of the “Top 30 Under 40” biotech leaders, and by GEN as one of the “Top 10 Under 40” leaders in biopharma research and business. He earned his B.S., M.D., and M.B.A. all from Duke University.